On 21 July 2026 the Indian Council of Medical Research (ICMR) licensed three indigenous biomedical technologies for commercialisation under its Medical Innovations Patent Mitra initiative.
Medical Innovations Patent Mitra
- Purpose: Technology transfer and commercialisation route for publicly funded biomedical research; links national institutes with industry for product development and licensing.
- Administrative link: ICMR functions under the Department of Health Research, Ministry of Health and Family Welfare.
Technologies Licensed (21 July 2026)
- SHetA2 (anti‑HPV therapeutic): Candidate for Cervical Intraepithelial Neoplasia (CIN); licensed to Emcure Pharmaceuticals for development and commercial use.
- Fusion‑protein typhoid vaccine: Targets Salmonella typhi; developed at ICMR‑NIRBI, Kolkata; licensed to Biological E Ltd.
- Recombinant multivalent enteric vaccine: Designed for protection against S. typhi, S. paratyphi and Shigella spp.; licensed to Biological E Ltd.
Technical and clinical points
- CIN grading: CIN 1, CIN 2, CIN 3 denote increasing levels of cervical epithelial dysplasia used to guide management.
- Vaccine platforms: Fusion‑protein vaccines combine antigenic domains; recombinant vaccines use engineered antigens to broaden serovar coverage.
IASPOINT Booster Facts
- ICMR institutes: NICPR—cancer prevention and research; NIRBI—bacterial infections research and vaccine R&D.
- Regulatory pathway: Commercialisation requires CDSCO approvals and clinical trials under the New Drugs and Clinical Trials Rules, 2019.
- Industry partners: Biological E and Emcure are Indian manufacturers with GMP and scale‑up capabilities for vaccine and pharma production.